Condition (MeSH)
Joint Instability
ClinicalTrials.gov lists 113 trials for Joint Instability or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
113 of the 113 trials are tagged with Joint Instability itself; the rest are tagged with a narrower condition beneath it.
When did Joint Instability trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 4
- Not applicable
- Observational
Top of scale: 14
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 13 |
| 2024 | 9 |
| 2023 | 11 |
| 2022 | 8 |
| 2021 | 14 |
| 2020 | 5 |
| 2019 | 10 |
| 2018 | 10 |
| 2017 | 3 |
Showing 10 of 25 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 9 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 12 months across 79 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Joint Instability trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 4 | 3 |
| Not applicable | 53 |
| Observational | 55 |
How many Joint Instability trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 11 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 6 |
| Completed | 71 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Joint Instability trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Aesculap AG | 3 |
| Peter Brehm GmbH | 3 |
Which drugs are being tested for Joint Instability? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DOXY | 1 |
| MethylSulfonylMethane (MSM) | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Exercise | 2 |
| prolotherapy solution of 20% dextrose | 2 |
| [PRP] platelet rich plasma | 1 |
| Triamcinolone 0.1% | 1 |
| Epidural Steroid Injection | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Joint Instability trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| INCREASED PAIN RIGHT HIP | 1 | 1 |
| NERUOPRAXIA AND PAIN | 1 | 1 |
| POSTRAUMATIC DISLOCATION LEFT SHOULDER | 1 | 1 |
| RECURRENT INSTABILITY | 1 | 1 |
Which publications cover Joint Instability? (1,135)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Effect of Wii Fit Rehabilitation on Balance, Functional Ability, and Risk of Falling in Patients With Chronic Ankle Instability: A Randomized Controlled Trial. | American journal of physical medicine & rehabilitation | 2026 | Yes |
| Comparative study between lateral extra-articular tenodesis versus anterolateral ligament reconstruction in combination with anterior cruciate ligament reconstruction. | Journal of orthopaedic surgery and research | 2026 | Yes |
| Multifactorial approach training for anterior shoulder instability after a Latarjet procedure: protocol for a randomised controlled trial. | BMJ open | 2026 | Yes |
| Epidemiology of ankle sprain and chronic ankle instability in elite adolescent dancesport athletes. | The Physician and sportsmedicine | 2025 | Yes |
| The Visual Assessment of Cup Position on Anteroposterior Pelvis Radiographs Before Revision Total Hip Arthroplasty for Instability Is Highly Deceiving. | Orthopedics | 2025 | Yes |
Showing 5 of 1,135 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.